[
    {
        "file_name": "IOVANCEBIOTHERAPEUTICS,INC_08_03_2017-EX-10.1-STRATEGICALLIANCEAGREEMENT.txt",
        "perturbation": [
            {
                "type": "Ambiguities - In Text Contradiction",
                "original_text": "1.1 Joint Steering Committee. The Parties will establish a joint steering committee (\"JSC\") of equal representation, comprised of three members from each Party, with the members of each Party collectively having one vote on all matters to be decided upon by the JSC. Each Party can appoint and replace its members in the JSC at its own discretion through timely written notice to the other Party. The Principal Investigators for each Study (as defined hereinafter) shall attend each JSC meeting, except in the event of exigent circumstances that do not permit such attendance.",
                "changed_text": "1.1 Joint Steering Committee. The Parties will establish a joint steering committee (\"JSC\") of equal representation, comprised of three members from LBIO and two members from MD Anderson, with the members of each Party collectively having one vote on all matters to be decided upon by the JSC. LBIO can appoint and replace its members in the JSC at its own discretion through timely written notice to the other Party. MD Anderson can only replace its members if they resign or are terminated from MD Anderson. The Principal Investigators for each Study (as defined hereinafter) shall attend each JSC meeting, except in the event of exigent circumstances that do not permit such attendance.",
                "explanation": "The original text states 'equal representation, comprised of three members from each Party.' The modified text contradicts this by stating 'three members from LBIO and two members from MD Anderson.' This creates ambiguity regarding the composition of the JSC and the equal representation clause. Also the text describing members removal varies between parties.",
                "location": "Section 1.1"
            },
            {
                "type": "Ambiguities - In Text Contradiction",
                "original_text": "4.1 Initial Funding. LBIO agrees to commit funding in an amount not to exceed $14,211,864.00 for the performance of the Studies during the Term (collectively, \"Initial Funding\"), with the Initial Funding specifically allocated as follows: (a) $[* * *] for an upfront payment, and a minimum of $[* * *] for enrollment and treatment of a minimum of 40 patients in the Study described in Exhibit I (i.e., the Minimum Enrollment Target as defined in Exhibit 1) or up to $[* * *] (an \"Individual Study Budget\") for enrollment and treatment of up to 60 patients in the Study described in Exhibit I (i.e., the Maximum Enrollment Target as defined in Exhibit 1); (b) $[* * *] (which shall also be considered an Individual Study Budget) for enrollment, manufacturing of product, and treatment of 30 patients in the Study described in Exhibit II; and (c) $[* * *] for the Study described in Exhibit III. LBIO shall pay the Initial Funding in accordance with Section 4.3. For clarity, the Initial Funding is Collaboration Funding.",
                "changed_text": "4.1 Initial Funding. LBIO agrees to commit funding in an amount not to exceed $14,211,864.00 for the performance of the Studies during the Term (collectively, \"Initial Funding\"), with the Initial Funding specifically allocated as follows: (a) $[* * *] for an upfront payment, and a minimum of $[* * *] for enrollment and treatment of a minimum of 40 patients in the Study described in Exhibit I (i.e., the Minimum Enrollment Target as defined in Exhibit 1) or up to $[* * *] (an \"Individual Study Budget\") for enrollment and treatment of up to 60 patients in the Study described in Exhibit I (i.e., the Maximum Enrollment Target as defined in Exhibit 1); (b) $[* * *] (which shall also be considered an Individual Study Budget) for enrollment, manufacturing of product, and treatment of 30 patients in the Study described in Exhibit II; and (c) $[* * *] for the Study described in Exhibit III. LBIO shall pay the Initial Funding in accordance with Section 4.3. For clarity, the Initial Funding is not Collaboration Funding, but is considered a donation.",
                "explanation": "The original text explicitly states that the 'Initial Funding is Collaboration Funding.' The modified text directly contradicts this by stating 'Initial Funding is not Collaboration Funding, but is considered a donation.' This introduces a direct conflict in the definition and nature of the funding, potentially impacting tax liabilities, usage restrictions, and reporting requirements.",
                "location": "Section 4.1"
            },
            {
                "type": "Ambiguities - In Text Contradiction",
                "original_text": "8.4 Obligations upon Termination. Upon expiration or termination of this Agreement, in addition to its other obligations hereunder, including Section 5.2, MD Anderson shall return to LBIO all of its Confidential Information and all Materials or, at LBIO's option, destroy or completely delete such Confidential Information and Materials, at LBIO's option. With respect to each item of Confidential Information and Materials destroyed or completely deleted, such destruction or complete deletion shall be certified in writing to LBIO. In the event that this Agreement is terminated prior to MD Anderson's receipt of all internal approvals to commence work on the Study Orders in Exhibit I, Exhibit II and/or Exhibit III, MD Anderson shall refund the Upfront Payment to LBIO.",
                "changed_text": "8.4 Obligations upon Termination. Upon expiration or termination of this Agreement, in addition to its other obligations hereunder, including Section 5.2, MD Anderson shall return to LBIO all of its Confidential Information and all Materials or, at MD Anderson's option, destroy or completely delete such Confidential Information and Materials, at MD Anderson's option. With respect to each item of Confidential Information and Materials destroyed or completely deleted, such destruction or complete deletion shall be certified in writing to MD Anderson. In the event that this Agreement is terminated prior to MD Anderson's receipt of all internal approvals to commence work on the Study Orders in Exhibit I, Exhibit II and/or Exhibit III, MD Anderson shall retain the Upfront Payment from LBIO.",
                "explanation": "The original text states 'at LBIO's option' for destroying Confidential Information and Materials, whereas the modified text changes it to 'at MD Anderson's option.' This creates ambiguity regarding the control over destruction of materials and information upon termination. Also the upfront payment is refunded in the original text, whereas it is retained in the modified text after termination.",
                "location": "Section 8.4"
            }
        ]
    }
]